Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data

Physics in Medicine and Biology

Volumn 57, Issue 19, 2012, Pages 6079-6101

  Titz, Benjamin ^a   Kozak, Kevin R ^a,b   Jeraj, Robert ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-ANGIOGENIC THERAPY; BEVACIZUMAB; CANCER THERAPY; CELLULAR PROLIFERATIONS; CLINICAL TRIAL; COMBINATION THERAPY; COMPUTATIONAL MODEL; COMPUTATIONAL MODELLING; DOSE LEVELS; DOSE RESPONSE; GROWTH FRACTION; IMAGING DATA; MODEL PARAMETERS; MODELLING FRAMEWORK; PET DATA; PHASE I; QUANTITATIVE AGREEMENT; THERAPEUTIC EFFECTS; TUMOUR CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

CELL PROLIFERATION; MOLECULAR IMAGING; OPTIMIZATION; POSITRON EMISSION TOMOGRAPHY; TUMORS;

PATIENT TREATMENT;

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; BIOLOGICAL MODEL; CELL HYPOXIA; CELL PROLIFERATION; COMPUTER SIMULATION; DRUG EFFECT; HUMAN; NEOPLASM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL HYPOXIA; CELL PROLIFERATION; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84866384085     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/57/19/6079     Document Type: Article

References (90)

1. Allegra C J et al 2011 Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08 J. Clin. Oncol. 29 11-6
2. Andre F, McShane L M, Michiels S, Ransohoff D F, Altman D G, Reis-Filho J S, Hayes D F and Pusztai L 2011 Biomarker studies: a call for a comprehensive biomarker study registry Nature Rev. Clin. Oncol. 8 171-6
3. Azoitei N et al 2010 Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours Gut 59 1316-30
4. Beasley N J, Wykoff C C, Watson P H, Leek R, Turley H, Gatter K, Pastorek J, Cox G J, Ratcliffe P and Harris A L 2001 Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density Cancer Res 61 5262-7
5. Billy F, Ribba B, Saut O, Morre-Trouilhet H, Colin T, Bresch D, Boissel J P, Grenier E and Flandrois J P 2009 A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy J. Theor. Biol. 260 545-62
6. Blancher C, Moore J W, Talks K L, Houlbrook S and Harris A L 2000 Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines Cancer Res 60 7106-13
7. Blankenberg F G, Katsikis P D, Tait J F, Davis R E, Naumovski L, Ohtsuki K, Kopiwoda S, Abrams M J and Strauss H W 1999 Imaging of apoptosis (programmed cell death) with 99mTc annexin V J. Nucl. Med. 40 184-91
8. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse F E, Paschke M, Zahn G and Cursiefen C 2007 Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis Invest. Ophthalmol. Vis. Sci. 48 2545-52
9. Brooks P C, Clark R A and Cheresh D A 1994 Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 569-71
10. Cai W, Zhang X, Wu Y and Chen X 2006 A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression J. Nucl. Med. 47 1172-80
11. Carmeliet P 2003 Angiogenesis in health and disease Nature Med. 9 653-60
12. Christian N, Lee J A, Bol A, De Bast M, Jordan B and Gregoire V 2009 The limitation of PET imaging for biological adaptive-IMRT assessed in animal models Radiother. Oncol. 91 101-6
13. de Groot J F, Fuller G, Kumar A J, Piao Y, Eterovic K, Ji Y and Conrad C A 2010 Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice Neurol. Oncol. 12 233-42
14. De Los Santos J F and Thomas G M 2007 Anemia correction in malignancy management: threat or opportunity? Gynecol. Oncol. 105 517-29
15. Deisboeck T S, Zhang L, Yoon J and Costa J 2009 In silico cancer modeling: is it ready for prime time ? Nature Clin. Pract. Oncol. 6 34-42
16. Desar I M, van Herpen C M, van Laarhoven H W, Barentsz J O, Oyen W J and van der Graaf W T 2009 Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy Cancer Treat. Rev. 35 309-21
17. Diamandis E P 2010 Cancer biomarkers: can we turn recent failures into success ? J. Natl Cancer Inst. 102 1462-7
18. Du J, Li F H, Fang H, Xia J G and Zhu C X 2008 Correlation of real-time gray scale contrast-enhanced ultrasonography with microvessel density and vascular endothelial growth factor expression for assessment of angiogenesis in breast lesions J. Ultrasound Med. 27 821-31
19. Duda D G, Batchelor T T, Willett C G and Jain R K 2007 VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects Trends Mol. Med. 13 223-30
20. Dvorak H F 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J. Clin. Oncol. 20 4368-80
21. Escudier B et al 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103-11
22. Ferrara N and Davis-Smyth T 1997 The biology of vascular endothelial growth factor Endocrinol. Rev. 18 4-25
23. Ferrara N, Hillan K J, Gerber H P and Novotny W 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Rev. Drug. Discov. 3 391-400
24. Folkman J 1971 Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1182-6
25. Folkman J 1974 Proceedings: tumor angiogenesis factor Cancer Res. 34 2109-13
26. Forsythe J A, Jiang B H, Iyer N V, Agani F, Leung S W, Koos R D and Semenza G L 1996 Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 Mol. Cell Biol. 16 4604-13
27. Fujita K, Sano D, Kimura M, Yamashita Y, Kawakami M, Ishiguro Y, Nishimura G, Matsuda H and Tsukuda M 2007 Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma Oncol. Rep. 18 47-51
28. Gerber H P and Ferrara N 2005 Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res. 65 671-80
29. Gevertz J L 2011 Computational modeling of tumor response to vascular-targeting therapies - part I. Validation Comput. Math. Methods Med. 2011 830515
30. Gordon M S, Margolin K, Talpaz M, Sledge G W Jr, Holmgren E, Benjamin R, Stalter S, Shak S and Adelman D 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J. Clin. Oncol. 19 843-50
31. Gorelik B, Ziv I, Shohat R, Wick M, Hankins W D, Sidransky D and Agur Z 2008 Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model Cancer Res. 68 9033-40
32. Grothey A and Galanis E 2009 Targeting angiogenesis: progress with anti-VEGF treatment with large molecules Nature Rev. Clin. Oncol. 6 507-18
33. Hanahan D and Weinberg R A 2011 Hallmarks of cancer: the next generation Cell 144 646-74
34. Harari P M et al 2011 Phase I trial of bevacizumab combined with concurrent chemoradiation for squamous cell carcinoma of the head and neck: preliminary outcome results J. Clin. Oncol. 29 5518
35. Hasan M R, Ho S H, Owen D A and Tai I T 2011 Inhibition of VEGF induces cellular senescence in colorectal cancer cells Int. J. Cancer 129 2115-23
36. Hattingen E, Jurcoane A, Bahr O, Rieger J, Magerkurth J, Anti S, Steinbach J P and Pilatus U 2011 Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study Neuro Oncol. 13 1349-63
37. Helmlinger G, Endo M, Ferrara N, Hlatky L and Jain R K 2000 Formation of endothelial cell networks Nature 405 139-41
38. Hicklin D J and Ellis L M 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J. Clin. Oncol. 23 1011-27
39. Huang S M et al 2002 Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa) Cancer Res. 62 4300-6
40. Jain R K 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58-62
41. Jain R K, Duda D G, Clark J W and Loeffler J S 2006 Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nature Clin. Pract. Oncol. 3 24-40
42. Jiang B H, Semenza G L, Bauer C and Marti H H 1996 Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension Am. J. Physiol. 271 C1172-80
43. Johnson N F et al 1997 DNA damage-inducible genes as biomarkers for exposures to environmental agents Environ. Health Perspect. 105 913-8
44. Kelly C J and Brady M 2006 A model to simulate tumour oxygenation and dynamic [18F]-Fmiso PET data Phys. Med. Biol. 51 5859-73
45. Keunen O et al 2011 Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma Proc. Natl Acad. Sci. USA 108 3749-54
46. Kim K J, Li B, Winer J, Armanini M, Gillett N, Phillips H S and Ferrara N 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 841-4
47. Kindler H L et al 2010 Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303) J. Clin. Oncol. 28 3617-22
48. Kohandel M, Kardar M, Milosevic M and Sivaloganathan S 2007 Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies Phys. Med. Biol. 52 3665-77
49. Koukourakis M I et al 2007 Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging Am. J. Clin. Oncol. 30 315-8
50. Krasnoperov R A and Gerasimov A N 2009 Probability density functions for axial ratios of sectioning profiles of anisotropically arranged elliptical microvessels Math. Biosci. 219 97-103
51. Liu W, Ahmad S A, Reinmuth N, Shaheen R M, Jung Y D, Fan F and Ellis L M 2000 Endothelial cell survival and apoptosis in the tumor vasculature Apoptosis 5 323-8
52. Loggini B et al 2003 CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma Pathol. Res. Pract. 199 705-12
53. Lu J F, Bruno R, Eppler S, Novotny W, Lum B and Gaudreault J 2008 Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemother. Pharmacol. 62 779-86
54. Mac Gabhann F, Ji J W and Popel A S 2007 VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle J. Appl. Physiol. 102 722-34
55. May D, Itin A, Gal O, Kalinski H, Feinstein E and Keshet E 2005 Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer Oncogene 24 1011-20
56. Motzer R J et al 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N. Engl. J. Med. 356 115-24
57. Murakami Y, Takamatsu H, Taki J, Tatsumi M, Noda A, Ichise R, Tait J F and Nishimura S 2004 18F-labelled annexin V: a PET tracer for apoptosis imaging Eur. J. Nucl. Med. Mol. Imaging 31 469-74
58. Muzi M et al 2005 Kinetic analysis of 3-deoxy-3-fluorothymidine PET studies: validation studies in patients with lung cancer J Nucl. Med. 46 274-82
59. Nagengast W B et al 2011 VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment Cancer Res 71 143-53
60. Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza E C, Nobori T, Nakamura S and Shiku H 2002 Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer Am. J. Hematol. 69 247-54
61. Ou G, Itasaka S, Zeng L, Shibuya K, Yi J, Harada H and Hiraoka M 2009 Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 75 463-7
62. Petit S F, Dekker A L, Seigneuric R, Murrer L, van Riel N A, Nordsmark M, Overgaard J, Lambin P and Wouters B G 2009 Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study Phys. Med. Biol. 54 2179-96
63. Presta L G, Chen H, O'Connor S J, Chisholm V, Meng Y G, Krummen L, Winkler M and Ferrara N 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593-9
64. Rapisarda A et al 2009 Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition Mol. Cancer Ther. 8 1867-77
65. Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E and Freyer G 2011 A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers Eur. J. Cancer 47 479-90
66. Rofstad E K, Henriksen K, Galappathi K and Mathiesen B 2003 Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts Cancer Res 63 4055-61
67. Schlageter K E, Molnar P, Lapin G D and Groothuis D R 1999 Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties Microvasc. Res. 58 312-28
68. Schoch H J, Fischer S and Marti H H 2002 Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain Brain 125 2549-57
69. Secomb T W, Hsu R, Park E Y and Dewhirst M W 2004 Green's function methods for analysis of oxygen delivery to tissue by microvascular networks Ann. Biomed. Eng. 32 1519-29
70. Semenza G L 2001 Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology Trends Mol. Med. 7 345-50
71. Senan S and Smit E F 2007 Design of clinical trials of radiation combined with antiangiogenic therapy Oncologist 12 465-77
72. Shah C et al 2009 Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer Clin. Cancer Res. 15 4712-21
73. Shweiki D, Itin A, Soffer D and Keshet E 1992 Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 843-5
74. Simoncic U and Jeraj R 2009 Voxel-based kinetic analysis method utilizing ROI fragmentation Med. Phys. 36 2817
75. Sinor A D, Irvin S M, Cobbs C S, Chen J, Graham S H and Greenberg D A 1998 Hypoxic induction of vascular endothelial growth factor (VEGF) protein in astroglial cultures Brain Res. 812 289-91
76. Stroobants S et al 2003 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur. J. Cancer 39 2012-20
77. Tanaka F et al 2001 Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody Clin. Cancer Res. 7 3410-5
78. Tannock I F 1972 Oxygen diffusion and the distribution of cellular radiosensitivity in tumours Br. J. Radiol. 45 515-24
79. Titz B and Jeraj R 2008 An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response Phys. Med. Biol. 53 4471-88
80. Toi M, Inada K, Suzuki H and Tominaga T 1995 Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression Breast Cancer Res. Treat. 36 193-204
81. Tsuji T, Sasaki Y, Tanaka M, Hanabata N, Hada R and Munakata A 2002 Microvessel morphology and vascular endothelial growth factor expression in human colonic carcinoma with or without metastasis Lab. Invest. 82 555-62
82. Ullrich R et al 2008 Glioma proliferation as assessed by 3-fluoro-3-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma Clin. Cancer Res. 14 2049-55
83. Van der Veldt A A et al 2012 Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs Cancer Cells 21 82-91
84. Wang Y, Fei D, Vanderlaan M and Song A 2004 Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro Angiogenesis 7 335-45
85. Wedam S B et al 2006 Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J. Clin. Oncol. 24 769-77
86. Willett C G et al 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nature Med. 10 145-7
87. Zatterstrom U K, Kallen A and Wennerberg J 1991 Cell cycle time, growth fraction and cell loss in xenografted head and neck cancer In Vivo 5 137-42
88. Zhou Q, Guo P and Gallo J M 2008 Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide Clin. Cancer Res. 14 1540-9
89. Zhu X, Wu S, Dahut W L and Parikh C R 2007 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am. J. Kidney Dis. 49 186-93
90. Zips D et al 2003 Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation Anticancer Res. 23 3869-76